TRAVERE THERAPEUTICS INC. - COMMON STOCK

Travere Therapeutics Provides Corporate Update and 2023 Outlook

09 يناير 2023 06:00:01 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 يناير 2023 15:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 ديسمبر 2022 16:00:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

16 نوفمبر 2022 16:00:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease

15 نوفمبر 2022 07:00:02 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

09 نوفمبر 2022 15:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Third Quarter 2022 Financial Results

27 أكتوبر 2022 15:01:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022

26 أكتوبر 2022 15:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Report Third Quarter 2022 Financial Results

20 أكتوبر 2022 15:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy

13 أكتوبر 2022 15:05:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 أكتوبر 2022 16:00:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 سبتمبر 2022 16:00:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

25 أغسطس 2022 15:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy

22 أغسطس 2022 06:00:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 أغسطس 2022 16:00:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Second Quarter 2022 Financial Results

04 أغسطس 2022 06:00:02 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Provides Regulatory Updates on its Development Programs

03 أغسطس 2022 15:05:01 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Report Second Quarter 2022 Financial Results

28 يوليو 2022 15:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 يوليو 2022 16:00:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 يونيو 2022 16:00:00 بحسب Nasdaq GlobeNewswire